The Power of Three: Helios Bioelectronics, GattaCo, and iAssay Unite to Clobber Infectious Disease
The Californer/10142392

SAN DIEGO - Californer -- From Athos, Porthos, and Aramis to Luke, Leia, and Han, something magical happens when three forces unite.

Today, a trio of cutting-edge companies announced a global collaboration that will enable nearly instant medical test results, bypassing traditional biological laboratories and forwarding critical data to doctors, hospitals and  health agencies.

"From COVID-19 to leukemia, patients and clinicians need fast and accurate diagnoses," said Lonnie Adelman, CEO of San Diego's iAssay. "This collaboration will revolutionize how scientific and medical data is produced, collected, and shared."

The techniques pioneered by these three companies – iAssay of San Diego, Calif.; GattaCo of Murrieta, Calif.; and Taiwan's Helios Bioelectronics – can be used by engineers as well as medical professionals.  Besides medical and scientific applications, soil or water samples,could be tested for toxins, minerals or other materials.

More on The Californer

• Rachel Farris, CPA Featured on The AJ Brown Show to Discuss Act 60 Tax Incentives
• Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
• Jade & Zelda Launch Virtually Human: A Groundbreaking Podcast Hosted by AI-Powered Virtual Humans
• Dr. Satyam Priyadarshy Joins Indemnify AI to Enrich AI Risk Financial Quantification
• $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader

"By using many strands," said Dr. Hardy Chan, CEO of Helios, "we are weaving a stronger rope."

Helios Bioelectronics is the developer of a multi-patented electrochemical chip, the FET Chip, which identifies targeted elements such as viral proteins or nucleic acids that can be used to identify diseases such as COVID-19. Sometimes called "lab on a chip," this nanotechnology enables a vast amount of information to be gathered through assays processed at the point-of-care that would otherwise rely on detection via laboratories.

Using its patented sample purification technology, GattaCo has developed a plasma separation tool, the A-PON™. The A-PON automatically separates plasma from whole blood collected from a finger-stick without needing a centrifuge. GattaCo is developing a blood analysis cartridge system that integrates its sample purification technology together with Helios Bioelectronics' FET Chip. This cartridge will be read by iAssay's SimpleTest™ base technology with an adaptor specifically developed for the Helios/GattaCo cartridge.

More on The Californer

• Fact: Trump lied — again. California gas prices remain lower than a week ago, month ago, and a year ago
• Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
• Top "We Buy Houses" Companies in Oakland, CA Announced — JiT Home Buyers Leads the Pack in 2025
• Ansira Appoints Amalia Thomas As Chief Revenue Officer
• Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates

iAssay's patented SimpleTest™ automatically interprets test and control indications on a variety of medical tests.  After SimpleTest™ produces a test result, the device transmits the results to the company's SimpleCloud™, where results can be viewed in a password protected portal by doctors, hospitals, state and federal agencies, or scientists for research.

"This partnership has the potential of saving time, yes, but also saving lives," said Dr. Michael McNeely, president of GattaCo. "Knowledge is power, and the sooner patients and their doctors understand what they are dealing with, the sooner they can seek the correct treatment."

"Health and safety are universal needs," said Helios' Chan. "We may be on the other side of the world from our California partners, but we stand shoulder-to-shoulder with them in this essential work."

Visit http://www.iassay.net for details.
Visit http://www.gattaco.com for details.
Visit heliosbioelectronics.com for details.